Nasdaq:US$13.89 (+0.03) | HKEX:HK$22.45 (+0.50) | AIM:£2.07 (+0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.